Citizens Financial Group Inc RI Has $9.64 Million Holdings in Eli Lilly And Co (NYSE:LLY)

Citizens Financial Group Inc RI lifted its holdings in Eli Lilly And Co (NYSE:LLY) by 3.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 74,282 shares of the company’s stock after purchasing an additional 2,358 shares during the period. Citizens Financial Group Inc RI’s holdings in Eli Lilly And Co were worth $9,639,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Athena Capital Advisors LLC bought a new position in shares of Eli Lilly And Co during the 4th quarter valued at $26,000. Wakefield Asset Management LLLP bought a new stake in Eli Lilly And Co during the fourth quarter valued at approximately $27,000. Larson Financial Group LLC purchased a new position in Eli Lilly And Co during the fourth quarter valued at approximately $29,000. Trust Department MB Financial Bank N A lifted its holdings in Eli Lilly And Co by 54.7% during the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after purchasing an additional 82 shares in the last quarter. Finally, Acima Private Wealth LLC purchased a new position in shares of Eli Lilly And Co in the fourth quarter worth $33,000. Institutional investors and hedge funds own 79.42% of the company’s stock.

In other news, VP Michael J. Harrington sold 16,000 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the sale, the vice president now owns 110,300 shares in the company, valued at $12,874,216. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Joshua L. Smiley bought 426 shares of the stock in a transaction dated Wednesday, June 5th. The stock was bought at an average price of $118.03 per share, with a total value of $50,280.78. Following the purchase, the chief financial officer now owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The disclosure for this purchase can be found here. In the last quarter, insiders sold 246,112 shares of company stock valued at $31,888,255. Insiders own 0.11% of the company’s stock.

Shares of NYSE:LLY opened at $112.21 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. Eli Lilly And Co has a 52-week low of $84.64 and a 52-week high of $132.13. The firm has a market capitalization of $114.90 billion, a PE ratio of 20.22, a P/E/G ratio of 2.10 and a beta of 0.27.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.01. The firm had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.31 earnings per share. On average, equities analysts anticipate that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Friday, May 17th were paid a $0.645 dividend. The ex-dividend date of this dividend was Thursday, May 16th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.30%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.

A number of research analysts have weighed in on the stock. BMO Capital Markets boosted their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Bank of America set a $129.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Thursday, March 21st. Citigroup set a $124.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Tuesday, February 26th. UBS Group initiated coverage on shares of Eli Lilly And Co in a research report on Wednesday, March 20th. They issued a “buy” rating and a $74.51 price objective for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of Eli Lilly And Co in a report on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 price target on the stock. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $119.99.

WARNING: This piece of content was reported by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.wkrb13.com/2019/06/12/citizens-financial-group-inc-ri-has-9-64-million-holdings-in-eli-lilly-and-co-nyselly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: What are no-load funds?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.